A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors AbbVie
- 09 Aug 2019 Planned End Date changed from 17 Feb 2021 to 15 Jun 2021.
- 09 Aug 2019 Status changed from not yet recruiting to recruiting.
- 31 Jan 2019 Planned End Date changed from 5 May 2020 to 17 Feb 2021.